Hydrochlorothiazide use and risk of nonmelanoma skin cancer:A nationwide case-control study from Denmark
Uložené v:
| Názov: | Hydrochlorothiazide use and risk of nonmelanoma skin cancer:A nationwide case-control study from Denmark |
|---|---|
| Autori: | Arnspang, Sidsel, Gaist, David, Johannesdottir Schmidt, Sigrun Alba, Hölmich, Lisbet Rosenkrantz, Friis, Søren, Pottegård, Anton |
| Zdroj: | Arnspang, S, Gaist, D, Johannesdottir Schmidt, S A, Hölmich, L R, Friis, S & Pottegård, A 2018, 'Hydrochlorothiazide use and risk of nonmelanoma skin cancer : A nationwide case-control study from Denmark', Journal of the American Academy of Dermatology, vol. 78, no. 4, pp. 673-681.e9. https://doi.org/10.1016/j.jaad.2017.11.042 |
| Rok vydania: | 2018 |
| Zbierka: | University of Southern Denmark: Research Output / Syddansk Universitet |
| Predmety: | Journal Article, antihypertensives, skin cancer, hydrochlorothiazide, pharmacology, cancer risk, nonmelanoma skin cancer, pharmacoepidemiology, Carcinoma, Basal Cell/chemically induced, Hydrochlorothiazide/adverse effects, Risk Assessment, Humans, Middle Aged, Male, Skin Neoplasms/chemically induced, Case-Control Studies, Denmark/epidemiology, Squamous Cell/chemically induced, Aged, 80 and over, Female, Antihypertensive Agents/adverse effects |
| Popis: | Background: Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. Objective: To examine the association between hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Methods: From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with hydrochlorothiazide use. Results: High use of hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. Limitations: No data on sun exposure were available. Conclusions: Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC. |
| Druh dokumentu: | article in journal/newspaper |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| DOI: | 10.1016/j.jaad.2017.11.042 |
| Dostupnosť: | https://portal.findresearcher.sdu.dk/da/publications/7b7e307e-7ea3-42d7-9ab4-575a01170ae1 https://doi.org/10.1016/j.jaad.2017.11.042 https://findresearcher.sdu.dk/ws/files/137606525/Hydrochlorothiazide_use_and_risk_of_non_melanoma_skin_cancer.pdf |
| Rights: | info:eu-repo/semantics/openAccess |
| Prístupové číslo: | edsbas.B53B77B5 |
| Databáza: | BASE |
Nájsť tento článok vo Web of Science | Abstrakt: | Background: Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. Objective: To examine the association between hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Methods: From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with hydrochlorothiazide use. Results: High use of hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. Limitations: No data on sun exposure were available. Conclusions: Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC. |
|---|---|
| DOI: | 10.1016/j.jaad.2017.11.042 |